Drugs / Valerian
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00070928 | Sep 2000 → Jun 2006 | Parkinson disease, insomnia | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00782080 | Jul 2008 → Mar 2010 | attention deficit-hyperactivity disorder | Prof. Huss | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05185219 | Dec 2021 → Jan 2025 | insomnia | China Medical University Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | valerian | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00070928 ↗ |
| Known as | Valerian Extract | “St. John´s Wort (100 mg) Valerian Extract (50 mg)” NCT00782080 ↗ |
| Route | Oral | “Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks” NCT00782080 ↗ |